OR WAIT null SECS
February 13, 2020
ERS Genomics revealed that the European Patent Office (EPO) has rejected arguments filed in opposition to patent EP2800811, which is directed to the single-guide CRISPR/Cas9 gene editing system and covers uses in cellular and non-cellular settings.
The Native Antigen Company has commercially introduced antigens that have been specifically derived from the Wuhan strain of novel coronavirus, now named Covid-19.
February 12, 2020
Through the agreement, Catalent will offer process optimization and drug substance manufacturing services for the drug candidate at its Madison, WI site.
February 10, 2020
New funding brings competitors, and a leading healthcare products distributor, into the standardization effort.
February 07, 2020
A growing number of pharma executives see investment in machine learning and big data as a top priority, according to a 2020 GlobalData survey.
February 06, 2020
Aimmune plans to introduce the antibody as an adjunctive treatment with its Characterized Oral Desensitized ImmunoTherapy programs to research treatment outcomes in patients with food allergies.
February 04, 2020
The vaccine is designed to provide active immunity against the influenza A (H5N1) strain and can be easily deployed in a pandemic event.
January 31, 2020
Abcam has purchased Applied StemCell’s (ASC’s) gene editing platform and oncology product portfolio, adding comprehensive cell editing capabilities and engine to support expansion of existing “off-the-shelf” cell lines.
The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.
Otsuka will use PhoreMost’s phenotypic screening platform to identify new targets for drug development, with a focus on gene therapy.